NeoGenomics Reports 10% Revenue Growth to $727M Despite -$0.84 FY EPS
NeoGenomics delivered full-year revenue of $727 million, up 10% from $661 million, but recorded a diluted EPS loss of $0.84. In Q4, the company posted an adjusted EPS of $0.06 versus estimates of $0.04 and revenue of $190 million, marking a 50% earnings surprise and a 10% year-over-year revenue gain.
1. Annual Financial Results
NeoGenomics recorded full-year revenue of $727 million, a 10% increase from $661 million a year earlier, while reporting a diluted net loss of $0.84 per share. The top-line outperformance contrasts with the EPS shortfall against consensus forecasts.
2. Fourth Quarter Results
In the quarter ending December 2025, the company generated revenue of $190 million, exceeding consensus estimates by roughly 1% and up from $172 million a year ago. Adjusted diluted EPS reached $0.06, a 50% surprise over the $0.04 forecast.
3. Historical Performance vs Expectations
Over the past four quarters, NeoGenomics has delivered adjusted EPS above consensus in three periods and surpassed revenue estimates twice, demonstrating consistent growth and operational resilience amid fluctuating market conditions.
4. Valuation and Liquidity Position
NeoGenomics trades at a negative trailing P/E of -12.5, a price-to-sales ratio of 2.06 and an EV/S ratio of 2.3, while maintaining a strong current ratio of 4.26. These metrics underline both its market valuation and liquidity strength.